Curis SEC Filings

Curis, Inc. filed an amended report to update timing details for its previously approved reverse stock split. The Reverse Stock Split Certificate of Amendment is expected to become effective on July 2, 2026 at 5:00 PM ET. Curis common stock is expected to begin trading on The Nasdaq Stock Market on a split-adjusted basis at market open on July 6, 2026. The shares will continue to trade under the ticker symbol “CRIS”, and the common stock will have a new CUSIP number following the reverse split.

Curis, Inc. is implementing a reverse stock split of its common stock at a 1-for-20 ratio. This means every 20 existing shares will be combined into 1 share, reducing the number of shares outstanding while proportionally increasing the price per share.

At a special meeting of stockholders held on June 25, 2026, stockholders approved amendments to the Restated Certificate of Incorporation allowing a reverse split in a range between 1-for-5 and 1-for-25. On the same date, the Board of Directors chose the specific 1-for-20 ratio.

Curis, Inc. held a special stockholder meeting on June 25, 2026, where investors approved a reverse stock split authorization. Stockholders adopted amendments to the Restated Certificate of Incorporation allowing the Board to implement a reverse split of the common stock at a ratio between 1-for-5 and 1-for-25, with discretion to choose the exact ratio or abandon the change.

The reverse split proposal received 26,898,163 votes for, 751,966 against, and 123,820 abstentions. A separate proposal to adjourn the meeting, if needed to secure additional votes, also passed but was not used.

Curis, Inc. is asking stockholders at a virtual special meeting on June 25, 2026 to approve amendments allowing a reverse stock split of its common stock at a ratio between 1‑for‑5 and 1‑for‑25, to be chosen later by the board within six months.

The main goal is to increase the share price to meet Nasdaq Capital Market bid‑price requirements after receiving a Nasdaq delisting determination for trading below the $1.00 minimum. The board argues a higher price could help preserve the listing and broaden institutional interest, though it warns the split may not sustain a higher price and could reduce liquidity and create odd lots.

The reverse split would not change total authorized shares of 567,514,300, would affect all stockholders proportionally, and fractional shares would be rounded up to the nearest whole share. A second proposal would allow the meeting to be adjourned to solicit more proxies if needed. As of May 21, 2026, 38,978,693 common shares were outstanding and entitled to vote.

Curis, Inc. is asking stockholders to approve amendments to its Restated Certificate of Incorporation to permit a reverse stock split of its common stock at a ratio set by the Board between 1-for-5 and 1-for-25. If approved, the Board may implement the Reverse Stock Split at any time within six months following stockholder approval or abandon it before filing.

The Special Meeting is virtual on June 25, 2026 (record date: May 21, 2026), and 38,978,693 shares were outstanding as of the record date. Proposal 2 would permit adjournment to solicit additional proxies. The Board recommends a FOR vote on both proposals.

Curis, Inc. reported that stockholders approved a major amendment to its charter to increase total authorized capital stock from 288,757,150 to 572,514,300 shares, including an increase in authorized common stock from 283,757,150 to 567,514,300 shares. The amendment became effective upon filing in Delaware.

The company also filed a Certificate of Elimination to remove the designations for its Series A Convertible Exchangeable Preferred Stock and Series B Convertible Non-Redeemable Preferred Stock, returning those shares to undesignated preferred stock. At the same annual meeting, two Class III directors were re-elected, executive compensation received majority support in a nonbinding vote, and PricewaterhouseCoopers LLP was ratified as independent auditor for the 2026 fiscal year.

Armistice Capital, LLC and Steven Boyd filed Amendment No. 3 to a Schedule 13G/A reporting beneficial ownership of 679,033 shares of Curis, Inc. common stock, representing 4.99% of the class. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., which is the direct holder, and that voting and dispositive power are exercised jointly through the Investment Management Agreement. The filing is signed by Steven Boyd as managing member and is dated May 15, 2026.

Curis, Inc. reports an amended Schedule 13G/A showing Thomas A. Satterfield, Jr. beneficially owns 3,957,950 shares of Common Stock, representing 9.9% (rounded) of outstanding stock.

The filing states 38,978,693 shares outstanding as of May 8, 2026 and describes warrants and pre-funded warrants that are subject to a 9.99% exercise limit. The report breaks out ownership held directly and through affiliated entities.

Curis, Inc. reported a net loss of $24.2 million for the three months ended March 31, 2026, more than double the prior-year period, as it transitions to being fully dependent on its IRAK4/FLT3 inhibitor emavusertib. Revenue fell to $0 from $2.4 million after the 2025 sale of Erivedge royalty rights. Research and development expenses declined 24% to $6.4 million, while general and administrative costs rose 27% to $5.1 million, driven largely by the January 2026 PIPE financing.

Curis ended the quarter with $15.0 million in cash and cash equivalents and used $9.0 million of cash in operations. The company explicitly states there is “substantial doubt” about its ability to continue as a going concern within one year without substantial additional capital, citing an accumulated deficit of about $1.3 billion and ongoing operating losses. Management plans to seek more financing and strategic options while focusing development on emavusertib in PCNSL and CLL.